NCT06563388

Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial

(ID-COMET) A Randomized Phase III Trial of Immediate Versus Six-Month Delayed Comprehensive Treatment of 1-10 Oligometastatic Tumors With or Without Synchronous Primary

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 800 (estimated)
• Sponsor: Roswell Park Cancer Institute · Academic / Other
• Sex: All
• Age: 1 Year
• Healthy volunteers: Not accepted

Summary

This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients with lung (Trial 1), colorectal (Trial 2), and prostate (Trial 3) cancers

Conditions

• Oligometastasis
• Lung Cancer
• Colo-rectal Cancer
• Prostate Cancer

Interventions

Type	Name	Description
PROCEDURE	Stereotactic Ablative Radiotherapy	Radiation therapy begins after 3 months of Standard of care
OTHER	Best Practice	Receive standard of care therapy

Timeline

• Start date: 2024-09-18
• Primary completion: 2032-09-18
• Completion: 2032-09-18
• First posted: 2024-08-20
• Last updated: 2026-02-04

Locations

1 site across 1 country: United States